Alkem Labs to grow chronic therapies, biosimilars to drive future growth: MD

Alkem Laboratories, a top-seller of antibiotics, is focusing on the chronic therapy segments and is investing heavily in biosimilars and contract development and manufacturing services, its managing director, Sandeep Singh, told ET. The Mumbai-based drug maker, which entered the US generics market over a decade ago, is also scaling back its investments on oral solids in the face of competition and price erosion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Tw9KgW5
via IFTTT